A Growing Category in Drug Development
Controlled substances have moved from the margins of pharmaceutical development to its centre. Psychedelic-assisted therapy programmes involving psilocybin, MDMA, and ketamine derivatives are advancing through Phase II and Phase III trials. Cannabis-derived medicines, opioid alternatives, and GABA-modulating compounds for neurological conditions all involve scheduled molecules. The renaissance of interest in controlled substances as therapeutic agents has created a category of drug development that requires specialist regulatory, manufacturing, and logistics expertise.
Working with controlled substances in a clinical development programme is not fundamentally different from working with any other class of active pharmaceutical ingredient, but it involves an additional layer of regulatory authorisations and compliance requirements at every stage that can significantly extend timelines if not planned for early.
The Regulatory Framework for Controlled Substances in Drug Development
The international framework for controlled substances is set by the United Nations 1961 Single Convention on Narcotic Drugs and the 1971 Convention on Psychotropic Substances, which classify controlled substances into schedules based on their therapeutic value and abuse potential, and require signatory states to implement national control measures. At the national level, different jurisdictions apply their own scheduling systems and regulatory requirements.
| Jurisdiction | Regulatory Authority | Key Requirement for Clinical Use | Scheduling Framework |
| United States | DEA (Drug Enforcement Administration) + FDA | Schedule I substances require DEA researcher licence; Schedule II-V require DEA registration. FDA IND required for clinical use. | Schedules I-V based on accepted medical use and abuse potential |
| European Union | National Competent Authorities (e.g. ANSM in France, BfArM in Germany) | Narcotic drug import/export licences required per shipment; CTA required for clinical use | National scheduling aligned broadly with UN conventions; varies by member state |
| Spain (Pamplona) | Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS) | Authorisation for manufacture and clinical use; detailed record-keeping requirements | Psicotropos and narcoticos scheduling under national legislation |
| United Kingdom | Home Office + MHRA | Home Office controlled drug licence required for Schedule 1 substances; Schedule 2-5 under standard conditions | Misuse of Drugs Regulations 2001 schedules |
Manufacturing Controlled Substances Under GMP
The manufacturing of controlled substances under GMP requires not only the standard quality systems applicable to any pharmaceutical product but also specific physical security measures, inventory control procedures, and record-keeping requirements mandated by the relevant national authority. Storage areas for Schedule I and II substances must typically be secured in dedicated locked enclosures with access restricted to authorised personnel, and all movements of controlled substance material must be recorded in a balance ledger that is subject to regulatory inspection.
Yield accounting is a critical element of controlled substance manufacturing under GMP. The mass balance for the drug substance and drug product must be demonstrable at each step of the process, and any discrepancies between theoretical and actual yield must be investigated and documented. This requirement adds a layer of process monitoring to controlled substance manufacturing that is less stringent for conventional pharmaceutical products.
Cross-Border Shipment of Controlled Substances
Moving controlled substances between countries for clinical trial purposes, whether from the manufacturer to a clinical supply depot or from a depot to an investigator site, requires import and export licences for each individual shipment in most jurisdictions. These licences are issued by national competent authorities and typically require information about the substance, the quantity, the consignee, and the purpose of the shipment.
The lead times for obtaining import and export licences vary significantly between countries and can range from a few days to several weeks or more. For multi-country clinical trials, coordinating the licence applications across all importing jurisdictions in advance of the planned shipment schedule is a specialist logistics task that must be factored into the programme timeline from the outset.
Planning for Controlled Substance Programmes
Secure Your Manufacturing Licences Early
The licence to manufacture a controlled substance for clinical use must be in place before any GMP manufacturing campaign begins, and obtaining it requires an application to the relevant national authority well in advance. For new substances, or for CDMOs adding a new controlled substance category to their existing licences, the application and inspection process can take several months. Starting this process at the beginning of the development programme, not at the time of the first GMP batch, is essential.
Design Your Stability Programme for Controlled Substance Compliance
Stability samples containing controlled substances must be stored under the same security conditions as the primary drug substance and drug product, and their movements must be subject to the same inventory controls. This affects the design of the stability storage programme and must be factored into the stability facility requirements.
Ardena’s Controlled Substance Capabilities at Pamplona
Ardena’s Pamplona facility in Spain holds authorisations for the manufacture and handling of controlled substances under Spanish and European regulatory requirements. The facility has the physical security infrastructure, inventory management systems, and procedural controls required for GMP manufacturing of scheduled compounds.
Ardena’s regulatory team at Pamplona has experience managing the licence applications and compliance requirements for controlled substance clinical programmes, including coordination with AEMPS and, where required, with the competent authorities of importing countries. For programmes targeting both European and US clinical sites, Ardena can advise on the coordination of European and DEA requirements.
